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NATURAL HISTORY
The spectrum and prognosis of AIDS-
defining illnesses in Cape Town




Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine,
and Department of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town
Objectives. To describe the incidence, spectrum and prognosis of AIDS-defining illnesses (ADI) in patients without access to
antiretroviral therapy (ART). 
Design. Prospective cohort study.
Subjects. 1 215 HIV-infected patients attending adult HIV clinics affiliated to the University of Cape Town in the New Somerset
and Groote Schuur Hospitals from 1992 to 2000. 
Main outcome measures. Incidence rate (IR) of ADIs and survival after the development of ADI.
Results. During follow-up, 430 ADIs occurred (IR = 21.3 cases per 100 patient-years (PYs)). IR varied according to CD4 count, with
38.8, 17.0 and 8.52 cases/100 PYs in patients with CD4 counts < 200 cells/µl, 200 - 350 cells/µl and > 350 cells/µl, respectively.
Tuberculosis (TB) was the commonest ADI, followed by candidiasis of the oesophagus/trachea/bronchi. IRs for chronic herpes
simplex ulcers, HIV wasting, Pneumocystis carinii pneumonia and Kaposi's sarcoma were > 1.00 cases/100 PYs. TB was diagnosed
in all CD4 strata, and was the only illness to occur commonly above 200 cells/µl. The median CD4 counts within 6 months of
diagnosis of ADI ranged from 138 cells/µl for TB to 17 cells/µl for cryptococcosis. Overall, median time to death from date of
diagnosis was 18 months, and ranged from 24.1 months for patients diagnosed with TB to 6 months for those diagnosed with
cytomegalovirus. 
Conclusions. HIV-infected patients with no access to ART in Cape Town are at high risk of AIDS-defining illnesses. This study
provides useful data for designing therapeutic interventions for preventing these infections.
HIV infection is characterised by progressive immune
suppression, which eventually results in the development of
opportunistic diseases.1-3 The spectrum of these infections
varies across the world, and is partially determined by the
organisms that are prevalent in the community.
The spectrum of severe HIV-related diseases in sub-Saharan
Africa is characterised by an abundance of virulent pathogens
such as Mycobacterium tuberculosis, Streptococcus
pneumoniae and Salmonella spp.4,5 Pneumocystis carinii
pneumonia (PCP) is uncommon, and avirulent organisms such
as cytomegalovirus (CMV) and M. avium complex are seldom
found.4,5 Tuberculosis (TB), bacterial infections and malaria are
the leading causes of HIV-related morbidity across sub-Saharan
Africa. In studies reporting CD4 count, the range of cell counts
at the time of diagnosis of severe HIV-related diseases is wide.4,5
While the spectrum of severe HIV-related diseases in
industrialised countries is well described, few published studies
exist describing the incidence and prognosis of HIV-related
diseases in Africa, and the level of immune suppression at
which these diseases occur. Most existing studies are of cross-
sectional design, and is difficult to compare them owing to
differences in referral patterns, study population, criteria for
HIV testing, diagnostic methods, and the disease reported.6
Sound incidence data on severe HIV-related events are
important for designing preventive or curative therapeutic
intervention.
The objectives of this analysis were to estimate the incidence of
AIDS-defining illness (stratified by CD4 count and WHO clinical
stage) and survival after the development of AIDS-defining
illness, and to describe the distribution of the CD4 count within
6 months of the onset of AIDS-defining illnesses in HIV-
infected patients with no access to antiretroviral therapy (ART). 
The analysis was based on the Cape Town AIDS Cohort (CTAC),
which comprises patients from the wide socio-demographic
METHODS
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spectrum of the Western Cape. CTAC is based on patients
attending public sector HIV health care services at New
Somerset Hospital (NSH) and Groote Schuur Hospital (GSH),
which are affiliated to the University of Cape Town. For the
purpose of this analysis, patients presenting with an AIDS-
defining illness at their initial clinic visit or receiving any form
of ART were excluded. 
Data on the CTAC patients were collected prospectively from
1992. Routine demographic, clinical and laboratory data were
collected using a standard computerised format. Patients
presented to the clinic approximately 3 - 6-monthly or more
frequently if clinically indicated. At each visit, patients were
examined for manifestations of HIV/AIDS-related illness and
staged using the World Health Organization (WHO) criteria.7 HIV
diagnosis was confirmed by enzyme-linked immunosorbent
assay (ELISA) and confirmed with Western blot (or subsequently
a second ELISA) on two different blood specimens. The CD4
count was measured approximately bi-annually, using flow
cytometry (Beckman Coulter®, Miami, Fla, USA). Vital status
data were acquired from the inpatient records, via notification
by family or the patient's general practitioner, or by reviewing
local death registries. The analysis was carried using Epi Info
(version 6.0; CDC, Atlanta, Ga, USA) and STATISTICA (release 6.6,
Tulsa, Oklahoma, USA).
AIDS-FREE SURVIVAL AND RISK OF DEATH FROM
ONSET OF AIDS
The Kaplan-Meier method was used to plot AIDS-free survival
curves by WHO stage and CD4 count from the initial clinic visit
date to the date of onset of an AIDS-defining illness. The same
method was used to measure risk of death from the onset of
AIDS. The analysis was further stratified by specific illness. CD4
count was measured ± 6 months from the initial clinic visit, if
not available at the date of the initial clinic visit. CD4 count was
categorised as < 200, 200 - 350 and > 350 cells/µl.
INCIDENCE OF AIDS-DEFINING ILLNESSES
The incidence rate (IR) for each diagnosis was calculated by
dividing the number of new diagnoses of the AIDS-defining
illness that occurred after entry into the cohort by the total
number of the person-years (PYs) of the cohort. The analysis
was further stratified by baseline CD4 count. The time spent in
each CD4 count stratum was summed, yielding PYs by CD4
count stratum, and the incidence rate of each AIDS-defining
illness was calculated as the number of new cases occurring
while in a given CD4 count stratum, divided by the total number
of PYs of observation in that CD4 count stratum. For each AIDS-
defining illness the distribution of CD4 counts (within ± 6
months of the diagnosis of the condition) was examined. All-
cause mortality was estimated for each AIDS-defining illness
using the Kaplan-Meier method. Follow-up was continued until
death, date last seen in the clinic or end-point of the study (31
December 2000). In this analysis, all sites of TB diagnosis
(pulmonary, extrapulmonary or disseminated) were included in
one group. 
STUDY SAMPLE
The study included 1 215 patients who did not use ART during
follow-up and had no AIDS-defining illness before the initial
clinic visit. The baseline characteristics of these patients are
described in Table I. The cohort consists mostly of young
indigent patients with a wide clinical and immune suppression
spectrum. Approximately 50% of these patients received
prophylactic cotrimoxazole at some point of their follow-up.
AIDS-FREE SURVIVAL
Median time to occurrence of an AIDS-defining illness varied
according to baseline CD4 count (ranging from 63 months for
patients with CD4 count > 350 cells/µl to 18 months in those
with CD4 count < 200 cells/µl) and WHO stage (ranging from
56 months for patients with WHO stage I to 18 months in those
with WHO stage III) (Fig. 1). 
INCIDENCE OF AIDS-DEFINING ILLNESSES
During a median 1.66 years of follow-up, 430 AIDS-defining
illnesses occurred (IR = 21.3 cases per 100 PYs, 95% confidence
interval (CI) 19.6 - 23.2) (Table II). Of these illnesses, 255
occurred in patients with CD4 count < 200 cells/µl (IR = 38.8
cases per 100 PYs, 95% CI 35.0 - 42.6), 108 illnesses in patients
with CD4 count 200 - 350 cells/µl (IR = 17.0 cases per 100 PYs,
95% CI 14.2 - 20.2), and 59 in patients with CD4 count > 350
cells/µl (IR = 8.52 cases per 100 PYs, 95% CI 6.6 - 10.9). Eight
illnesses occurred in 30.1 PYs of follow-up in patients with
unknown CD4 count (IR = 26.7, 95% CI 12.3 - 45.9 cases per
100 PYs). Incidence ranged from 10.6 cases per 100 PYs for TB
to 0.05 cases per 100 PYs for endemic mycosis.
Age (mean ± SD) (yrs) 31.3 (± 8.89)
CD4 count
< 200 cells/µl 415 (34.2%)
200 - 350 cells/µl 319 (26.3%)
> 350 cells/µl 446 (36.7%)
Not done 35 (2.8%)
Median (interquartile range) 276.5 (143.5 - 437.0)
WHO stage
Stage I 547 (45%)
Stage II 210 (17.3%)
Stage III 458 (37.7%)







SD = standard deviation.
TABLE I. BASELINE CHARACTERISTICS OF THE COHORT
RESULTS
make up JUNE issue nicky  5/30/05  1:18 PM  Page 12
JUNE 2005                                                THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE14
CD4 COUNT AT DIAGNOSIS OF
AIDS-DEFINING ILLNESSES
At (or ± 6 months of) the date of
diagnosis, median CD4 counts ranged
from 138 cells/µl for TB cases to 17




Overall, median time to death from date
of diagnosis was 18 months. Median
survival ranged from 24.1 months for
patients diagnosed with TB to 6 months
for those diagnosed with CMV (Table III).
This study reported high rates of AIDS-
defining illnesses among HIV-infected
patients living in Cape Town with no
access to highly active antiretroviral
therapy (HAART). The IR of these illnesses
was high at low CD4 cell strata,
particularly in the < 200 cells/µl stratum.
TB was the commonest illness, followed
by candidiasis of the oesophagus/
trachea/bronchi or lungs. Herpes simplex
virus (HSV) infection, wasting, Pneumo-
cystis carinii pneunomia (PCP) and
Kaposi's sarcoma had an IR > 1.00 cases
per 100 PYs. Disseminated mycosis,
progressive multifocal leukoencephalo-
pathy and lymphoma were rare. TB was
diagnosed in all CD4 strata, and was the
only illness to occur commonly above
200 cells/µl. This study is one of only a
few that have assessed the incidence of
the AIDS-defining illnesses in Africa,
stratified both by CD4 count and WHO
clinical stage. However, the pre-
ponderance of TB and the level of
immune suppression at which it occurs,
and the overall spectrum of illnesses, is
consistent with other reports from the
region.5,8-10 Of note is the fact that most
of the illnesses diagnosed in this cohort
are preventable or are amenable to
treatment. The incidence estimates and
time to AIDS according to baseline CD4
count and WHO stage, and survival
following the onset of each AIDS-
Median AIDS-free survival (months) 
CD4 > 350 CD4 200 - 350 CD4 < 200 Stage 1 Stage 2 Stage 3
63 41 18 56 39 18
Overall < 200 cells/µl 200 - 350 cells/µl > 350 cells/µl 
Illness (2014.8 PYs) (657.5 PYs) (635.1 PYs) (692.1 PYs) N/A
No. Incidence No. Incidence No. Incidence No. Incidence
1 Tuberculosis 214 10.6 111 16.88 62 9.76 39 5.64 2
2 Candidiasis of O/T/B/L 57 2.83 40 6.08 13 2.05 2 0.29 2
3 HSV 27 1.34 19 2.89 7 1.10 1 0.14 0
4 Wasting 27 1.34 15 2.28 6 0.94 6 0.87 0
5 PCP 24 1.19 15 2.28 6 0.94 3 0.43 0
6 Kaposi's sarcoma 23 1.14 17 2.59 2 0.31 3 0.43 1
7 Cryptococcosis 13 0.65 9 1.37 2 0.31 1 0.14 1
8 Encephalopathy 11 0.55 5 0.76 4 0.63 1 0.14 1
9 Cryptosporidiosis 10 0.50 8 1.22 0 0 1 0.14 1
10 Disseminated atypical 
mycobacteria 8 0.40 5 0.76 3 0.47 0 0 0
11 CMV 6 0.30 4 0.61 1 0.16 1 0.14 0
12 Lymphoma 4 0.20 4 0.61 0 0 0 0 0
13 Toxoplasmosis 3 0.15 3 0.46 0 0 0 0 0
14 PML 2 0.10 0 0 2 0.31 0 0 0
15 Mycosis 1 0.05 1 0.15 0 0 0 0 0
Total 430 21.34 256 38.94 108 17.01 58 8.38 8
Incidence = per 100 PY; Candidiasis of O/T/B/L = candidiasis of the oesophagus, trachea, bronchi or lungs;  
PML = progressive multifocal leukoencephalopathy.
TABLE II. INCIDENCE OF AIDS-DEFINING ILLNESSES IN 1 215 HIV-INFECTED PATIENTS WITH NO ACCESS TO HAART
(1992 - 2000) BY CD4 COUNT STRATA
Fig. 1. Kaplan-Meier probabilities of AIDS-free survival according to baseline CD4
count category and WHO stage.
DISCUSSION
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defining illness calculated in this study, are useful data for
designing and assessing the outcome of therapeutic
interventions for preventing and treating these infections.
Survival after AIDS in Africa may be shorter than in
industrialised countries. This may be due to high prevalence of
virulent pathogens in the environment and lack of access to
health care. In a recent review, Holmes et al.5 observed that in
sub-Saharan Africa, TB and bacterial infections are the major
cause of morbidity and mortality among hospitalised patients.
Bacteraemia, particularly caused by non-typhoid salmonellae
and S. pneumoniae, and associated with cryptosporidia and
Isospora belli, are the most frequently isolated pathogens. Non-
typhoid salmonellae and Shigella species are also commonly
isolated when stool cultures are performed. Cerebral
toxoplasmosis, and meningitis due to Cryptococcus
neoformans, tuberculosis and bacterial pathogens, are the most
frequent neurological infections. Infections with atypical
mycobacteria,  Pneumocystis carinii and CMV are rare.5 They
also found that, compared with industrialised countries, death
occurs at a higher range of CD4 counts, although still in the
range consistent with advanced disease. 
The findings of this study have important implications for
health care management of HIV-infected patients. Very few
infections preventable by cotrimoxazole occurred at CD4 counts
> 200 cells/µl. This suggests a limited beneficial effect for
prophylactic cotrimoxazole in patients with CD4 counts at this
level. The high incidence of TB across the different CD4 count
strata indicates that preventive therapy with isoniazid should
be considered early in the course of HIV disease.
This study had the following limitations. Cause of death was
not ascertained, and therefore all-cause mortality was reported.
As such, we are unable to exclude non-HIV-related causes of
death. Median follow-up of 19.9 months is relatively short and
reflects the difficulty of maintaining long follow-up in this
setting. It is therefore possible that the actual incidence rate of
the various infections reported among this cohort might have
been underestimated.
In conclusion, in HIV-infected patients without access to HAART
in Cape Town, the overall risk of AIDS-defining illnesses is high
and increases with lower CD4 counts and more advanced WHO
clinical stage. Early prevention and treatment of these
infections will result in large health benefits. Guidelines for
therapeutic interventions for prevention of AIDS-defining
illness, including ART, in this region should be tailored
according to the spectrum and epidemiology of these
infections.
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Condition All TB WAS KS HSV PCP CRYPS CAND Enc Lymph CRYPO ATYP CMV
Median 18.1 24.1 22.2 17.8 17 14 13.9 9.5 8.6 7.6 6.5 6.4 6.1
survival
TABLE III. KAPLAN-MEIER PROBABILITIES OF SURVIVAL FOLLOWING DIAGNOSIS.
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TB = all forms of TB; ENC = HIV encephalopathy; PCP = Pneumocystis
carinii pneumonia; TOXO = toxoplasmosis; HSV = herpes simplex virus; KS
= Kaposi's sarcoma; WAS = HIV wasting syndrome; CRYS =
cryptosporidiosis with diarrhoea > 1 month; CAND = candidiasis of the
oesophagus, trachea, bronchi or lungs; ATYP = disseminated atypical
mycobacteriosis; CMV = cytomegalovirus; LYM = lymphoma; CRYB =
extrapulmonary cryptococcosis.
Fig. 2. CD4 count distribution at (or ± 6 months of) the date of
diagnosis.
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